Micafungin

Also called: Mycamine; FK463; Micafungin sodium

What it is

A daily intravenous echinocandin, first approved as Mycamine (2005); the brand is discontinued and generics are marketed.

Approval status

FDA Approved. Approved in the US as Mycamine (Astellas), NDA 021506, on March 16, 2005; Mycamine products are listed as discontinued, while generic micafungin (ANDAs from 2019) and a Baxter ready-to-use premix (NDA 216142, September 29, 2023) are marketed (Drugs@FDA via openFDA and the micafungin label, read October 3, 2026).

Dosing, as printed in the page's Recommended Dosing box

Manufacturer's recommended dosing (FDA label)

From the prescribing information. Other doses studied, if any, are in the full dosing data below.

Protocol and source	Dose	Frequency	Duration	Route
Label: candidaemia, disseminated candidiasis, Candida peritonitis and abscesses (adults) **[Approved label]** Micafungin for injection US prescribing information (Hisun Pharmaceuticals; DailyMed set 230fcff4, effective April 14, 2026)	100 mg	Once daily	Mean 15 days in responders (range 10-47)	Intravenous, over 1 hour
Label: oesophageal candidiasis (adults) **[Approved label]** Micafungin for injection US prescribing information (Hisun Pharmaceuticals; DailyMed set 230fcff4, effective April 14, 2026)	150 mg	Once daily	Mean 15 days in responders (range 10-30)	Intravenous, over 1 hour
Label: prophylaxis in stem cell transplant recipients (adults) **[Approved label]** Micafungin for injection US prescribing information (Hisun Pharmaceuticals; DailyMed set 230fcff4, effective April 14, 2026)	50 mg	Once daily	Mean 19 days in responders (range 6-51)	Intravenous, over 1 hour
Label: children 4 months and older, candidaemia **[Approved label]** Micafungin for injection US prescribing information (Hisun Pharmaceuticals; DailyMed set 230fcff4, effective April 14, 2026)	2 mg/kg (maximum 100 mg)	Once daily	Set by prescriber	Intravenous, over 1 hour

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for "research use only" are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

Key human evidence

The first 3 of the 11 human studies carded on the page (11 study cards in all):

• **Against liposomal amphotericin B** (Human, 2007). Among 531 randomised patients with candidaemia or invasive candidiasis, treatment success in the per-protocol analysis was 89.6% on micafungin and 89.5% on liposomal amphotericin B, a difference of 0.7 points, regardless of Candida species, site or neutropenia. **PMID 17482982**

• **Against caspofungin** (Human, 2007). In 595 patients, about 85% with candidaemia, treatment success at the end of blinded intravenous therapy was 76.4% on micafungin 100 mg, 71.4% on 150 mg and similar on caspofungin. **PMID 17806055**

• **Prophylaxis after stem cell transplantation** (Human, 2004). In 882 adults and children undergoing stem cell transplantation, prophylaxis success was 80.0% on micafungin against 73.5% on fluconazole (difference 6.5 points, P = 0.03). **PMID 15546073**

Interactions

From the FDA label's drug-interaction section (Baxter. Micafungin in Sodium Chloride Injection US prescribing information, section 7. DailyMed version of September 29, 2023, read October 3, 2026):

• With sirolimus, itraconazole, nifedipine: monitor for toxicity of these drugs and reduce their dose if necessary (FDA label)

• With cyclosporine, itraconazole, voriconazole, fluconazole, rifampin, ritonavir: did not alter micafungin pharmacokinetics (FDA label)

Side effects and cautions

Reported side effects	Contraindications and cautions
• Safety comparable to liposomal amphotericin B and caspofungin in the treatment trials	• Hypersensitivity reactions • Blood (haematological), liver and kidney effects • Infusion and injection-site reactions • High sodium load with the premixed product

Five questions to ask

1. Is Micafungin right for me, and is the labelled dose on this sheet right for my weight, age, kidney and liver function?
2. Here are the medicines and supplements I take. Do any of them interact with Micafungin? This sheet lists the interactions on record.
3. Which side effects should make me stop and call you, for example safety comparable to liposomal amphotericin b and caspofungin in the treatment trials?

4. Do any of the cautions on this sheet apply to me, such as: Hypersensitivity reactions?
5. What should we check before I start and while I am on it (blood tests, blood pressure, weight), and how often?

Grey Peptides is a vendor-neutral encyclopedia: it sells nothing and names no seller. This sheet is educational, not medical advice, and is not a prescription.